Breastfeeding may decrease risk of pediatric acute lymphoblastic leukemia
the ONA take:
According to a new study, researchers from Telethon Kids Institute in Perth, Australia, have found that breastfeeding a child may reduce that child's risk of developing pediatric acute lymphoblastic leukemia (ALL).
For the study, researchers assessed whether breastfeeding, introducing solid foods, or early diet were associated with ALL or childhood brain tumors (CBT). Mothers of both healthy children and children with ALL or CBT completed a questionnaire about their child's dietary consumption up until the child was 2 years of age.
Mothers were asked whether they breasted their child and for what duration, whether they used baby formula, and when they started feeding their child solid foods. Results showed that children who were fed with formula were more likely to develop ALL, which researchers suggest is due to the absence of breastfeeding.
They found no link between breastfeeding and CBT, which may be because brain tumors develop through a different mechanism versus ALL. The researchers note that evidence is only suggestive of an association.
Breastfeeding a child may reduce that child's risk of developing pediatric acute lymphoblastic leukemia (ALL).
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- Ruxolitinib Effective as Long-term Treatment Option for Polycythemia Vera
- Study Affirms Activity of Ibrutinib in Patients With R/R CLL With 17p Deletion
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- Longer Maintenance Therapy Duration May Improve Survival in Myeloma
- HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma
- Economic Evaluation of Obinutuzumab in Combination With Chlorambucil in First-line Treatment of Patients With Chronic Lymphocytic Leukemia in Spain
- MRD Assessment Improves PFS Prediction in Patients With CLL
- Cancer Patients Have Unrealistic Hopes When Entering Clinical Trials
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|